Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Castle Biosciences Inc's Business Segments
Castle Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 84
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 84 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Non-Dermatologic50.9%
- Dermatologic49.1%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Non-Dermatologic | $ 43 | 50.9% |
| Dermatologic | $ 41 | 49.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Castle Biosciences Inc
Castle Biosciences Inc is a medical technology company that specializes in molecular diagnostics for skin cancer. The company is based in Friendswood, Texas, and was founded in 2008 by Derek Maetzold, James Patterson and Federico Monsonego.
Castle Biosciences’ mission is to improve patients’ lives through the development of highly accurate and clinically actionable diagnostics for challenging cancer types. The company focuses on developing and commercializing genomic-based diagnostic tests that provide physicians and patients with accurate information to help identify the most effective treatment options.
The company’s flagship diagnostic test is DecisionDx®-Melanoma, a gene expression profile test that provides an individualized risk assessment for patients with cutaneous melanoma. The test is designed to help physicians determine which patients are at high risk of recurrence and who would benefit from closer surveillance and more aggressive treatment.
In addition to DecisionDx®-Melanoma, Castle Biosciences has developed diagnostic tests for uveal melanoma, cutaneous squamous cell carcinoma, and other cancers. The company also offers a suite of testing services for physicians, including gene expression profiling, next-generation sequencing, and pathology services.
Castle Biosciences has a robust research and development program, with a team of scientists and bioinformaticians working to identify new biomarkers and diagnostic tests for other types of cancer. The company is committed to advancing precision medicine by integrating genomic tools into clinical practice and providing patients with individualized treatment options based on their genetic profile.
The company has been recognized for its innovative work in cancer diagnostics, receiving the 2020 Clinical Diagnostics Company of the Year award from Frost & Sullivan. Castle Biosciences also recently went public in 2019 and is traded on the NASDAQ under the ticker “CSTL”.
Overall, Castle Biosciences Inc is a leading medical technology company that is helping to advance the field of precision medicine by developing highly accurate and clinically actionable diagnostics for challenging cancer types.
Castle Biosciences’ mission is to improve patients’ lives through the development of highly accurate and clinically actionable diagnostics for challenging cancer types. The company focuses on developing and commercializing genomic-based diagnostic tests that provide physicians and patients with accurate information to help identify the most effective treatment options.
The company’s flagship diagnostic test is DecisionDx®-Melanoma, a gene expression profile test that provides an individualized risk assessment for patients with cutaneous melanoma. The test is designed to help physicians determine which patients are at high risk of recurrence and who would benefit from closer surveillance and more aggressive treatment.
In addition to DecisionDx®-Melanoma, Castle Biosciences has developed diagnostic tests for uveal melanoma, cutaneous squamous cell carcinoma, and other cancers. The company also offers a suite of testing services for physicians, including gene expression profiling, next-generation sequencing, and pathology services.
Castle Biosciences has a robust research and development program, with a team of scientists and bioinformaticians working to identify new biomarkers and diagnostic tests for other types of cancer. The company is committed to advancing precision medicine by integrating genomic tools into clinical practice and providing patients with individualized treatment options based on their genetic profile.
The company has been recognized for its innovative work in cancer diagnostics, receiving the 2020 Clinical Diagnostics Company of the Year award from Frost & Sullivan. Castle Biosciences also recently went public in 2019 and is traded on the NASDAQ under the ticker “CSTL”.
Overall, Castle Biosciences Inc is a leading medical technology company that is helping to advance the field of precision medicine by developing highly accurate and clinically actionable diagnostics for challenging cancer types.
Castle Biosciences Inc. is a forward-thinking medical technology company focused on enhancing cancer diagnosis and treatment through precision medicine. Its innovative products and services are designed to deliver accurate diagnostic insights and predictive information, ultimately improving patient outcomes in oncology and dermatology. Below is an extensive overview of the companys segments, products, and services.
Segments
1. Oncology:
Castle Biosciences operates primarily within this segment, focusing on the genomics of various cancers, particularly skin cancers such as melanoma, uveal melanoma, and cutaneous squamous cell carcinoma (cSCC). The genomic tests developed by Castle aim to provide critical prognostic and therapeutic information that supports oncologists in treatment decision-making.
2. Dermatology:
In the dermatology segment, Castle focuses on non-invasive genetic testing for skin lesions that may indicate malignancy. This genre of testing is intended to reduce unnecessary invasive procedures and lead to more precise treatment plans.
Products
1. DecisionDx-UM:
This genomic test is focused on uveal melanoma, a rare yet aggressive form of eye cancer. It evaluates the activity of 15 genes within the tumor tissue, categorizing patients as either high-risk or low-risk. This stratification is crucial for guiding treatment decisions such as the need for adjuvant therapy or more aggressive monitoring.
2. DecisionDx-SCC:
Aimed at cutaneous squamous cell carcinoma, this test assesses the expression of 40 genes in the tumor. The results yield insights into the likelihood of metastasis and recurrence, providing doctors with a clearer picture of a patient’s prognosis and aiding in treatment planning.
3. DecisionDx-Melanoma:
This test is pivotal for patients diagnosed with melanoma, the most aggressive form of skin cancer. It examines 31 genes and assigns risk levels (low-risk or high-risk) for both recurrence and metastasis, enabling tailored follow-up and treatment strategies.
4. DecisionDx-DiffDx Melanoma:
Designed to differentiate between malignant melanoma and benign nevi, this test employs gene expression analysis to enhance diagnostic accuracy. By identifying whether a lesion is likely malignant, it can help reduce the number of unnecessary biopsies and surgeries, which can be burdensome for patients.
5. DecisionDx-UMSeq:
This genomic test provides a detailed analysis of DNA mutations specifically in uveal melanoma. The insights gained from this analysis can inform treatment options, monitoring strategies, and overall patient management.
6. Skin Cancer Genomic Test:
This non-invasive test targets suspicious pigmented skin lesions that may suggest skin cancer. By analyzing 40 genes, it assesses the probability of melanoma versus non-melanoma skin cancers, offering crucial information to dermatologists for early and accurate diagnosis.
Services
1. Biobank Services:
Castle Biosciences provides biobank services aimed at the collection and preservation of patient samples. This facility supports future diagnostic endeavors and research, fostering advancements in genomic testing and cancer care.
2. Data Analytics Services:
The company offers data analytics services that assist healthcare professionals in interpreting genomic test results. These services enhance the clinical utility of the genomic information, ensuring that it informs optimal patient management strategies.
3. Medical Education and Training:
Recognizing the complexities involved in genomic testing, Castle Biosciences provides educational programs aimed at healthcare professionals. These initiatives focus on the application and interpretation of genomic tests, supporting practitioners in integrating these tools into their clinical practice effectively.
4. Patient Advocacy and Support:
Castle Biosciences collaborates with patient advocacy groups to offer essential resources and support structures for patients and their families. This commitment to patient-centered care underscores the companys dedication to improving the cancer journey for those affected.
In conclusion, Castle Biosciences Inc. stands at the forefront of cancer diagnostics and treatment through its extensive offering of genomic tests, all tailored to enhance the accuracy of diagnoses and personalize treatment plans for patients. The company’s commitment to innovative solutions is evidenced not only in its products but also in its supporting services that foster an integrated approach to cancer patient care.
Segments
1. Oncology:
Castle Biosciences operates primarily within this segment, focusing on the genomics of various cancers, particularly skin cancers such as melanoma, uveal melanoma, and cutaneous squamous cell carcinoma (cSCC). The genomic tests developed by Castle aim to provide critical prognostic and therapeutic information that supports oncologists in treatment decision-making.
2. Dermatology:
In the dermatology segment, Castle focuses on non-invasive genetic testing for skin lesions that may indicate malignancy. This genre of testing is intended to reduce unnecessary invasive procedures and lead to more precise treatment plans.
Products
1. DecisionDx-UM:
This genomic test is focused on uveal melanoma, a rare yet aggressive form of eye cancer. It evaluates the activity of 15 genes within the tumor tissue, categorizing patients as either high-risk or low-risk. This stratification is crucial for guiding treatment decisions such as the need for adjuvant therapy or more aggressive monitoring.
2. DecisionDx-SCC:
Aimed at cutaneous squamous cell carcinoma, this test assesses the expression of 40 genes in the tumor. The results yield insights into the likelihood of metastasis and recurrence, providing doctors with a clearer picture of a patient’s prognosis and aiding in treatment planning.
3. DecisionDx-Melanoma:
This test is pivotal for patients diagnosed with melanoma, the most aggressive form of skin cancer. It examines 31 genes and assigns risk levels (low-risk or high-risk) for both recurrence and metastasis, enabling tailored follow-up and treatment strategies.
4. DecisionDx-DiffDx Melanoma:
Designed to differentiate between malignant melanoma and benign nevi, this test employs gene expression analysis to enhance diagnostic accuracy. By identifying whether a lesion is likely malignant, it can help reduce the number of unnecessary biopsies and surgeries, which can be burdensome for patients.
5. DecisionDx-UMSeq:
This genomic test provides a detailed analysis of DNA mutations specifically in uveal melanoma. The insights gained from this analysis can inform treatment options, monitoring strategies, and overall patient management.
6. Skin Cancer Genomic Test:
This non-invasive test targets suspicious pigmented skin lesions that may suggest skin cancer. By analyzing 40 genes, it assesses the probability of melanoma versus non-melanoma skin cancers, offering crucial information to dermatologists for early and accurate diagnosis.
Services
1. Biobank Services:
Castle Biosciences provides biobank services aimed at the collection and preservation of patient samples. This facility supports future diagnostic endeavors and research, fostering advancements in genomic testing and cancer care.
2. Data Analytics Services:
The company offers data analytics services that assist healthcare professionals in interpreting genomic test results. These services enhance the clinical utility of the genomic information, ensuring that it informs optimal patient management strategies.
3. Medical Education and Training:
Recognizing the complexities involved in genomic testing, Castle Biosciences provides educational programs aimed at healthcare professionals. These initiatives focus on the application and interpretation of genomic tests, supporting practitioners in integrating these tools into their clinical practice effectively.
4. Patient Advocacy and Support:
Castle Biosciences collaborates with patient advocacy groups to offer essential resources and support structures for patients and their families. This commitment to patient-centered care underscores the companys dedication to improving the cancer journey for those affected.
In conclusion, Castle Biosciences Inc. stands at the forefront of cancer diagnostics and treatment through its extensive offering of genomic tests, all tailored to enhance the accuracy of diagnoses and personalize treatment plans for patients. The company’s commitment to innovative solutions is evidenced not only in its products but also in its supporting services that foster an integrated approach to cancer patient care.